CD28 and myeloid sarcoma: As observed in MS patients (17), CD28-mediated IL-17A gene expression was delayed (24 h) when compared with IL-6 (6 h), thus suggesting that CD28-induced production of IL-6 in turn cooperates with CD28 signaling in mediating IL-17A gene expression.